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There is actually no consensus about the possibility that in some instances, obesity may be a benign metabolically healthy (MH)
condition as opposed to a normal-weight but metabolically unhealthy (MUH) state. The aim of this study was to characterize
MH condition and to investigate possible associations with metabolic and cardiovascular complications. One thousand nineteen
people (range of age 18–90 years) of the cohort of the ABCD_2 study were investigated. Participants were classiﬁed as normal
weight (BMI< 24.9 kg/m2) or overweight-obese (BMI≥25 kg/m2); they were also classiﬁed as MH in the presence of 0-1 among
the following conditions: (a) prediabetes/type 2 diabetes, (b) hypertension, (c) hypertriglyceridemia or low HDL cholesterolemia,
and (d) hypercholesterolemia. MUH condition was diagnosed if ≥2 of the conditions listed were found. The prevalence of
overweight/obese people was 71.1%, of whom 27.4% were found to be MH. In addition, 36.7% of the normal-weight participants
were MUH. HOMA-IR, high sensitivity C-reactive protein, and the carotid intima-media thickness were signiﬁcantly diﬀerent
in the 4 subgroups (P < 0 001), with higher values observed in the MUH normal-weight and obese groups. In conclusion,
this study highlights the importance of identifying a MH condition in normal-weight and in obese people in order to oﬀer
better treatment.
1. Introduction
Obesity is a widespread condition in the Western world [1],
and its prevalence is continuously increasing, even in emerg-
ing countries [2]. Parallel to obesity, the prevalence of type 2
diabetes (T2D), hypertension, and atherosclerotic cardiovas-
cular disease is rising [3]. It has not been deﬁnitively estab-
lished to what extent obesity is responsible for the epidemic
of metabolic and cardiovascular comorbidities or if these
conditions are more directly the consequence of unfavorable
changes that deteriorate people’s lifestyle in terms of seden-
tary habits and poor diet [4–6]. In fact, given the interaction
between genotype and lifestyle, it has been hypothesized that
obesity is not always uniquely responsible for classical
comorbidities such as diabetes and atherosclerosis and that
cases of uncomplicated obesity are not rare [7]. This point
of view is of interest because, otherwise, we would character-
ize more than half of the adult population as sick.
It has therefore been proposed to classify obese people
as metabolically healthy (MH) and unhealthy (MUH) [8].
Interestingly, as diabetes and atherosclerosis can occur even
in normal-weight people, the MH and MUH conditions have
also been applied to normal-weight people. Therefore, it is
not rare to ﬁnd normal-weight MUH individuals who have
a worse prognosis thanMH-O individuals [9]. This approach
would be of particular usefulness in personalizing treatment
Hindawi
Journal of Diabetes Research
Volume 2017, Article ID 9294038, 9 pages
https://doi.org/10.1155/2017/9294038
and selecting subclasses of people in whom to potentiate
interventions. Unfortunately, there is no consensus on the
deﬁnition of MH and MUH conditions, and general
population-based studies are scarce [10–12].
In this study, we investigated the association between
MH and MUH conditions, deﬁned on the basis of the
components of metabolic syndrome and of blood cholesterol
concentrations, with diﬀerent cardiovascular and metabolic
outcomes in a comprehensive general population cohort
who participated in the second evaluation, in 2015, of the
nutrition, cardiovascular wellness and diabetes (ABCD_2)
study [13]. The aim was to characterize MH condition
with respect to body size and investigate possible associations
with factors predisposing to metabolic and cardiovascular
complications.
2. Materials and Methods
The ABCD_2 project (ISRCTN15840340) is a longitudinal
observational single-center study of a cohort representative
of the general population living in Palermo, the largest city
in Sicily, Italy, with a population of 674742. The ABCD study
cohort was recruited in 2011, as previously described [13].
The demographic characteristics of the ABCD cohort were
similar, even if nonoverlapping, to those of the general pop-
ulation of the same range of age (18–90 years) living in
Palermo in 2011, as presented elsewhere [14] (Table 1). The
original cohort was recontacted (telephone, e-mail, and let-
ter) in 2015, and those who agreed to participate in the study
were asked to come to the Metabolism and Clinical Nutrition
Laboratory of the Department of Internal and Specialized
Medicine at the University of Palermo and were reexamined
from March 21 to July 31. Each participant was given the
opportunity to invite a relative or friend as a new participant
in the study, but the number of new participants was limited
to the ﬁrst 300 people. The demographic characteristics of
the ABCD_2 cohort were not signiﬁcantly diﬀerent from
those of the ABCD_1 cohort, as presented in Table 1.
Our institutional Ethics Committee (“Palermo 1” of the
Policlinico “P. Giaccone” University Hospital, November
03, 2014, ref: 3/2015) approved the study protocol, and each
participant signed an approved informed consent form.
Participants were administered a questionnaire on
demographic characteristics, the presence of chronic dis-
eases, and pharmacologic treatment. In particular, a speciﬁc
questionnaire was developed for deﬁning the individual level
of habitual physical activity (HPA). The physical activity
questionnaire consisted of the following 4 questions concern-
ing the type and the frequency of exercise: (a) do you regu-
larly engage in structured physical exercise (including walks
of at least 20 minutes)?; (b) if yes, what kind of physical exer-
cise?; (c) how many times a week?; and (d) what is your job?
Thus, on the basis of both intensity and frequency of physical
exercise and considering participants doing physically
demanding jobs, 4 diﬀerent levels of HPA were deﬁned: (a)
very low (no habitual exercise), (b) low (walks of 20–30
minutes at least 3 times a week); (c) medium (scheduled
physical activity 1–3 times a week or walks> 30 minutes
at least 3 times a week), and (d) high (scheduled physical
activity> 3 times a week or competitive sport activity or
heavy-job activity). The list of heavy-job activities is
reported in Table 2. Furthermore, housewives under the
age of 65, with children, were considered at a medium
HPA or higher if the criteria were met for deﬁning high
HPA. We validated the HPA questionnaire in comparison
(26 external participants, 7 females and 19 males, BMI:
31.0± 10.3 kg/m2) with 7-day pedometer measurements
(nonobese: 5986± 1793 versus obese: 5328± 3027 steps/day;
P = 0 54), obtaining signiﬁcant correlations between the
two methods (r = 0 57; P = 0 003).
Half-quantitative habitual intakes of diﬀerent foods dur-
ing the past 12 months were assessed using a food frequency
questionnaire (FFQ) validated for the local population [15].
Participants underwent blood sampling for assessment
of blood chemistry and hormonal parameters. For each
participant, a blood sample was frozen and stored at
−80°C for subsequent measurements. T2D and prediabetes
were deﬁned according to the most recent consensus state-
ments [16]. Arterial hypertension was deﬁned as systolic
blood pressure values≥ 130mmHg or diastolic blood pres-
sure values≥ 85mmHg or antihypertensive medication use;
triglyceride concentrations≥ 150mg/dl or lipid-lowering
medication use deﬁned hypertriglyceridemia. Low HDL
cholesterol levels were deﬁned if <40mg/dl for men and
<50mg/dl for women [17]. Hypercholesterolemia was
deﬁned as values> 200mg/dl or use of cholesterol-lowering
medication [18]. Participants were classiﬁed as MH if they
had 0-1 conditions of the following: prediabetes/T2D, hyper-
tension, hypertriglyceridemia or low HDL cholesterolemia,
and hypercholesterolemia. Participants were deﬁned as
MUH if they had at least 2 of the conditions listed above.
Height and body weight were measured with participants
lightly dressed and without shoes (SECA); the body mass
index (BMI) was calculated as body weight (kg)/height2
(m2). Normal-weight (N) participants were deﬁned if BMI
values< 25 kg/m2; overweight/obese (O) people were deﬁned
if BMI values≥ 25 kg/m2 [19]. Body circumferences were
measured at the umbilicus (waist circumference) and at the
most prominent buttock level (hip circumference); the
waist-to-hip ratio (WHR) was used as an indirect index of
body fat distribution. Systolic and diastolic arterial blood
pressure (two measurements obtained at 5-minute intervals
in seated position) and heart rate (Omron M6; Omron
Healthcare Co., Matsusaka, Mie, Japan) were measured by
physicians or dietitians according to standardized proce-
dures. Body composition in terms of fat mass (FM) and
fat-free mass (FFM) was estimated using bioelectrical imped-
ance analysis (BIA; BIA-103; RJL, Detroit, USA/Akern,
Florence, Italy) following the manufacturer’s equations, as
previously described [20].
The ankle-brachial index (ABI) was calculated as a mea-
sure of peripheral arterial obstructive disease and as a bio-
marker associated with mortality risk according to recent
guidelines [21, 22]. Bilateral arm and ankle blood pressure
values were measured, with the participant supine, with an
automated oscillometric device that used a wireless and
computerized system (iHealth Pro; iHealth Labs Europe,
Paris, France). The ABI was calculated as the ratio of
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ankle-to-brachial systolic pressure. The worst ABI value of
the 2 sides was considered for calculations. Participants
were deﬁned as having normal ABI measures if between
0.90 and 1.40.
Images of the right and left extracranial carotid artery
walls were obtained in several projections with a high-
resolution ultrasonographic 10MHz linear array probe
(Sonoline G50; Siemens, Germany). When an optimal longi-
tudinal image was obtained, it was frozen and stored on dig-
ital support for subsequent oﬀ-line measurements of intima-
media thickness (c-IMT). The end-diastolic c-IMT of the far
wall of both common carotid arteries was measured as
described elsewhere [23] and according to current guidelines
[24]. The maximum value between right and left carotid c-
IMT was considered for calculations. Two physicians were
responsible for carrying out the carotid ultrasonographic
examinations. The intraobserver coeﬃcients of variation
were, respectively, 1.2 and 1.1%; the between-observer coeﬃ-
cient of variation was 2.9%.
Ultrasonography of the abdomen was performed using a
3.5MHz convex probe (Sonoline G50; Siemens, Germany) by
a single trained physician for diagnosing the presence of
abdominal aorta (AA) aneurysm, liver steatosis, and gallblad-
der stones. AA aneurysm was diagnosed, according to recent
guidelines [25], as the presence of focal dilatation of
AA>3 cm. Liver steatosis was deﬁned as the presence of at
least one of the following: bright liver echo pattern (ﬁne,
packed, and high-amplitude echoes with consequent bright-
ness of the liver), increased liver-kidney contrast, possible
evidence of vascular blurring, and deep attenuation signs
[26]. Gallstone screening was done according to current
guidelines [27].
Fasting plasma glucose (FPG), total cholesterol, high-
density lipoprotein (HDL) cholesterol, triglycerides (Tg), uric
acid, and creatinine concentrations were ascertained using
standard clinical chemistry methods (Glucosio HK UV,
Colesterolo tot. Mod P/D, Colesterolo HDL gen 3 mod P/
917, Trigliceridi, Acido urico MOD P/917, and Creatininaen-
zimatica; Roche Diagnostics, Monza, Italy). Basal insulin
concentrations (Elecsysinsulina; Roche Diagnostics, Monza,
Italy), high sensitivity C-reactive protein (hs-CRP; B-
analyst hsCRP; Menarini diagnostics, Florence, Italy), and
glycated hemoglobin (HbA1c; B-analyst HbA1c; Menarini
diagnostics, Florence, Italy) were also measured. Low-
density lipoprotein (LDL) cholesterol serum concentration
was calculated with Friedewald’s formula [28], glomerular ﬁl-
tration rate (eGFR) was estimated based on the CKD-EPI
equation [29], and the HOMA-IR was calculated as described
by Matthews et al. [30].
Data are reported as means± SD for continuous variables
and as percentages for categorical variables. Normal distribu-
tion of values of continuous variables of interest was tested
using the Shapiro-Wilk test. The Student’s t-test for indepen-
dent samples was used to compare continuous variables
between 2 groups, while the χ2 test was used to compare cat-
egorical variables. Participants were classiﬁed into 4 groups
according to body size and metabolic health (MH-N,
MUH-N, MH-O, and MUH-O). In the case of continuous
variables, ANOVA evaluated diﬀerences in means between
groups, and Tukey’s post hoc test was used for comparison
between groups. If signiﬁcant diﬀerences were found for
variables such as age, gender, smoking habits, and sedentary
lifestyle, they were accounted for. Therefore, diﬀerences in
categorical variables in the 4 groups were analyzed using
the χ2 test, with stratiﬁcation for age, gender, smoking habits,
and sedentary lifestyle when signiﬁcantly diﬀerent. Similarly,
if signiﬁcantly diﬀerent between groups, these variables were
accounted for when evaluating diﬀerences between the 4
groups in continuous variables of interest (HOMA-IR, hs-
CRP, eGFR, ABI, and c-IMT) using ANCOVA. In addition,
their corrected values were calculated and presented as
mean± SEM. Pearson correlation coeﬃcients were calculated
to explore the associations among continuous variables. A
two-tailed P value of <0.05 was considered signiﬁcant. All
analyses were done using Systat (Windows version 13.0;
San Jose, CA, USA).
3. Results
A total of 1033 participants (415 males and 618 females)
were selected. Among them, 12 participants were excluded
because of incomplete data and 2 participants were
excluded because of pregnancy. Finally, a total of 1019
participants (408 males and 611 females) were evaluated.
The prevalence of overweight was 40.4%; that of obesity
was 30.7%. The physical, biochemical, and clinical charac-
teristics of participants divided into 2 groups according to
the presence of overweight-obesity are reported in Table 3.
Continuous variables presented in Table 3 were normally
distributed. Of the overweight-obese participants, 27.4%
were MH; 36.7% of the normal-weight participants were
MUH. The characteristics of the cohort divided into 4 groups
according to the presence of overweight-obesity and meta-
bolic health (MH-N, MUH-N, MH-O, and MUH-O) are
reported in Table 4. The MUH subgroups (both the N and
Table 2: List of physically demanding jobs.
Jobs considered medium
HPA level (M)
Jobs considered high
HPA level (H)
Housewife (<65 years) with children
Mechanic
Truck driver
Welder
Varnisher
Tinsmith
Laborer
Carpenter
Painter
Plumber
Bricklayer
Woodworker
Baker
Metalworker
Farmer
Docker
HPA= habitual physical activity.
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the O) exhibited higher age and prevalences of male gender
and sedentary lifestyle. In Table 4, the prevalences of coro-
nary heart disease (CHD), AA aneurism, gallbladder stones,
and liver steatosis are reported, which were stratiﬁed for
age, gender, and sedentary lifestyle. As reported in Table 5,
age-, gender-, and sedentary lifestyle-corrected values of
HOMA-IR, hs-CRP, and c-IMT were signiﬁcantly diﬀerent
among the 4 subgroups, and higher values were observed
in the MUH-N and MUH-O subgroups; no diﬀerences
were observed for eGFR-, creatinine- (P = 0 54), and ABI-
corrected values. The values of ABI and c-IMT were inversely
correlated (Figure 1).
4. Discussion
This study investigated a general population cohort in whom
the overall prevalence of overweight and obesity was very
high (about 70%). This ﬁnding is in agreement with that
expected in the adult population living in Sicily, in the south
of Italy [31]. Compared with the normal-weight group, the
overweight-obese group was older and with a higher preva-
lence of male gender; it also included more sedentary people
and fewer smokers. With the exception of the prevalence of
AA aneurysm and ABI values, which were not diﬀerent
between the normal-weight and overweight-obese groups,
the overweight-obese group exhibited a signiﬁcantly higher
prevalence of comorbidities, higher values of c-IMT, and
worse blood concentrations of all variables considered in this
study concerning metabolism, kidney function, and inﬂam-
mation. Therefore, we stratiﬁed the cohort in 4 subgroups
on the basis of BMI class and MH or MUH conditions. There
is a lack of consensus on the criteria to deﬁne MH, and, in
general, those used in diﬀerent studies were based on diﬀer-
ent combinations of the components of the metabolic
Table 3: Physical and biochemical characteristics of the cohort divided according to the presence of overweight-obesity.
Normal-weight
(BMI< 25 kg/m2)
Overweight-obesity
(BMI≥ 25 kg/m2) P
a
n (%) 294 (28.9) 725 (71.1)
Male (%) 32.0 43.3 <0.001
Age 45± 15 55± 13 <0.001
Smokers (%) 21.4 14.5 0.01
Physical inactivity (%) 55.6 62.4 0.04
Body weight (kg) 60.4± 8.2 81.1± 14.9 <0.001
BMI (kg/m2) 22.7± 1.7 30.7± 4.8 <0.001
Waist circumference (cm) 82.9± 7.5 102.2± 11.3 <0.001
Phase angle BIA (°) 6.8± 1.1 6.9± 2.8 0.29
Type 2 diabetes (%) 2.7 10.5 <0.001
Hypertension (%) 16.0 41.3 <0.001
CHD (%) 1.0 5.4 <0.001
AA aneurysm (%) 1.7 1.5 0.83
Cholelithiasis (%) 7.8 13.8 0.01
Hepatic steatosis (%) 25.9 53.0 <0.001
Blood concentrations
hs-CRP (mg/dl) 0.16± 0.28 0.29± 0.44 <0.001
Cholesterol (mg/dl) 199± 40 207± 41 0.005
LDL cholesterol (mg/dl) 118± 38 127± 36 <0.001
HDL cholesterol (mg/dl) 66± 17 58± 16 <0.001
Triglycerides (mg/dl) 81± 46 108± 58 <0.001
Uric acid (mg/dl) 4.4± 1.1 5.1± 1.3 <0.001
Glucose (mg/dl) 86± 12 95± 22 <0.001
Insulin (mU/ml) 6.75± 3.39 12.1± 9.16 <0.001
HbA1c (%) 5.3± 0.5 5.6± 0.7 <0.001
HOMA-IR 1.46± 0.91 2.95± 3.05 <0.001
eGFR (ml/min/1.73m2) 99.8± 16.9 90.6± 17.4 <0.001
ABI 1.08± 0.07 1.08± 0.07 0.21
c-IMT max (mm) 0.61± 0.21 0.72± 0.22 <0.001
Mean ± SD or percentages. aStudent’s t-test for independent samples, χ2 test if appropriate; CHD: coronary heart disease; AA: abdominal aorta; ABI: ankle-
brachial index; BIA: bioelectrical impedance analysis; BMI: body mass index; c-IMT max: maximum carotid intima-media thickness; eGFR: estimated
glomerular ﬁltration rate; HbA1c: glycated hemoglobin; HDL: high-density lipoproteins; HOMA-IR: homeostasis model assessment of insulin resistance;
hs-CRP: high-sensitivity C-reactive protein; LDL: low-density lipoproteins.
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syndrome. Consequently, based on the diagnostic criteria
used, large diﬀerences have been reported concerning the
prevalence of MH-O, ranging from 3 to 57% of obese patients
[32, 33]. Probably due to the very stringent criteria adopted
for deﬁning MH (presence of no more than 1 abnormality)
in our study, also including serum levels of cholesterol, as
suggested by Karelis et al. [34], we observed that about 70%
(corresponding to a prevalence of about 51.6% in the entire
cohort) of the overweight-obese participants were MUH, a
percentage that is similar to that observed in larger cohorts
[35]. We also found that about 35% of normal-weight partic-
ipants (about 10% of the cohort) were MUH too. As
expected, older age, male gender, and a sedentary lifestyle
characterized the MUH groups. Our ﬁndings are in agree-
ment with those of one study [36], but in contrast with those
of others. Phillips et al. found that lower physical activity was
not associated with MUH condition, even though the ques-
tionnaires for describing the physical activity level were sim-
ilar to those used in our study. They also used diﬀerent
criteria to stratify their cohort [37]. After stratiﬁcation for
age, gender, and sedentary lifestyle, we observed that MUH
condition was associated with higher prevalence of coronary
heart disease and AA aneurysm. The prevalence of AA aneu-
rysm was higher in the MUH-N than in the MUH-O group.
In fact, abdominal fat may induce atherosclerosis even in AA
individuals [38], but it is probably a mechanical protective
Table 4: Physical and biochemical characteristics of the cohort divided according to the presence of overweight-obesity and diabetes-
prediabetes, hypertension, and hypertriglyceridemia or low HDL cholesterol (healthy = 0-1 conditions; unhealthy = at least 2 conditions).
Normal-weight Overweight-obesity
Pa
Healthy (n = 187) Unhealthy (n = 97) Healthy (n = 202) Unhealthy (n = 530)
Male (%) 24.6 45.4 30.2 48.5 <0.001
Age 39± 12b,c,d 57± 12c 47± 13b,d 59± 11 <0.001
Smokers (%) 20.9 21.6 12.9 15.2 0.07
Physical inactivity (%) 51.6 63.9 49.0 67.3 <0.001
Body weight (kg) 60.1± 7.9c,d 60.3± 8.5c,d 70.6± 14.2d 82.7± 14.9 <0.001
BMI (kg/m2) 22.4± 1.7c,d 23.2± 1.4c,d 29.1± 4.6d 31.2± 4.8 <0.001
Waist circumference (cm) 80.9± 6.9b,c,d 86.5± 7.1c,d 96.8± 10.7d 104.0± 11.1 <0.001
Phase angle BIA (°) 6.8± 1.1 6.6± 1.3 6.8± 1.1 6.9± 3.2 0.72
Prevalence of (%)
CHD 0 3.1 1.0 7.0 <0.001
AA aneurysm 0 4.2 0 2.3 <0.001
Cholelithiasis 4.8 13.4 10.5 15.1 0.01
Hepatic steatosis 25.1 28.1 40.5 57.2 <0.001
Insulin (mU/ml) 6.38± 3.15 7.51± 3.66 9.13± 5.57 13.9± 9.97 0.13
HOMA-IR 1.33± 0.79d 1.74± 1.08d 1.94± 1.26d 3.32± 3.41 <0.001
hs-CRP (mg/dl) 0.15± 0.30d 0.18± 0.25 0.26± 0.42 0.30± 0.45 <0.001
eGFR (ml/min/1.73m2) 105.3± 14.6b,c,d 89.4± 16.6c 99.7± 16.9d 87.3± 16.3 <0.001
ABI 1.08± 0.07 1.07± 0.07 1.09± 0.06 1.08± 0.07 0.05
c-IMT max (mm) 0.54± 0.13b,c,d 0.74± 0.27c 0.62± 0.19d 0.76± 0.21 <0.001
Mean ± SD or percentages. aANOVA or χ2 test (stratiﬁed by age, gender, and physical inactivity) if appropriate. P < 0 05 versus bnormal-weight unhealthy,
cobese healthy, and dobese unhealthy; CHD: coronary heart disease; AA: abdominal aorta; ABI: ankle-brachial index; BIA: bioelectrical impedance analysis;
BMI: body mass index; c-IMT max: maximum carotid intima-media thickness; eGFR: estimated glomerular ﬁltration rate; HbA1c: glycated hemoglobin;
HDL: high-density lipoproteins; HOMA-IR: homeostasis model assessment of insulin resistance; hs-CRP: high-sensitivity C-reactive protein; LDL: low-
density lipoproteins.
Table 5: Estimated means of the dependent variables corrected for the covariates age, gender, and physical inactivity.
Normal-weight Overweight-obesity
Pa
Healthy (n = 187) Unhealthy (n = 97) Healthy (n = 202) Unhealthy (n = 530)
HOMA-IR 1.39± 0.22 1.72± 0.28 1.97± 0.19 3.29± 0.12 <0.001
hs-CRP (mg/dl) 0.12± 0.04 0.19± 0.05 0.25± 0.03 0.32± 0.02 0.006
eGFR (ml/min/1.73m2) 94.1± 1.1 93.1± 1.3 94.5± 0.9 92.7± 0.5 0.08
ABI 1.08± 0.01 1.07± 0.01 1.09± 0.01 1.08± 0.01 0.56
c-IMT max (mm) 0.66± 0.01 0.70± 0.02 0.67± 0.01 0.70± 0.01 <0.001
Mean ± SD; aANCOVA; ABI: ankle-brachial index; c-IMTmax: maximum carotid intima-media thickness; eGFR: estimated glomerular ﬁltration rate; HOMA-
IR: homeostasis model assessment of insulin resistance; hs-CRP: high-sensitivity C-reactive protein.
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factor for the AA wall [39]. We also found that prevalences of
gallbladder stones and liver steatosis were associated with
body size category and metabolic health, even after stratify-
ing for age, gender, and sedentary lifestyle. Gallbladder
stones are frequently associated with diabetes [40], while liver
steatosis, apart from being a condition frequently associated
with diabetes, is considered to have an important role in pro-
moting atherosclerosis itself [41]. Insulin resistance, as sug-
gested by corrected HOMA-IR values, was higher in
association with both overweight-obesity and MUH condi-
tion; a similar trend was also observed for hs-CRP blood con-
centrations. Apart from possible genetic inﬂuences that were
not investigated in this study, insulin resistance can be signif-
icantly promoted by both inﬂammation and sedentary life-
style and, accordingly, was associated with MUH condition
in our study. In agreement with other studies, the absence
of signiﬁcant inﬂammation, even in the low-grade range,
may be deemed as a characterizing trait of MH condition
[42–44], thus favoring a low metabolic and cardiovascular
risk proﬁle. We conﬁrm the importance of central body fat
distribution as a factor associated with metabolic and cardio-
vascular complications [45]. In fact, like the MUH-O group
that exhibited BMI and waist circumference values in accor-
dance with a more pronounced degree of central obesity, the
MUH-N group had uniquely higher values of waist circum-
ference with respect to the MH-N group. Interestingly, the
prevalence of cardiovascular diseases (coronary heart disease
and AA aneurism) was higher in the MUH-N group than in
the MH-O group. This result is in agreement with that of a
recent report on a large population-based cohort from
NHANES III [46], which found higher total and cardiovascu-
lar mortality in people with normal BMI and central distribu-
tion of fat than in BMI-deﬁned obese people, particularly in
the absence of central fat distribution. In agreement with
these results, the value of corrected c-IMT was lower in
MH groups than in MUH people, and the MUH-N group
had a higher value of c-IMT than the MH-O group. Current
guidelines [47] recommend the measurement of ABI for
stratifying the cardiovascular risk and the screening of
peripheral arterial disease. Though we found a signiﬁcant
correlation between ABI and c-IMT, in this study, the value
of ABI was not signiﬁcantly diﬀerent among any of the
groups considered. A possible explanation is that the ABI
value is compromised for advanced stages of arterial damage,
thus not an adequate indicator of vascular involvement in the
general population, while it is probably a more reliable indi-
cator in subgroups of people at higher risk [48]. Taken as a
whole, these data may suggest that cardiovascular measures
were associated with metabolic health independent of BMI
categories, while overweight-obesity associated with MUH
condition had an adjunctive unfavorable eﬀect on metabolic
measures. Finally, the phase angle is a bioelectrical body
characteristic that is related to the extra-/intracellular water
ratio, an interesting measure that is associated with nutri-
tional state and good health [49]; however, we found no sig-
niﬁcant diﬀerences of the phase angle value between the 4
groups considered in this study, thus suggesting that at least
the nutritional state was comparable.
Our study has the merit of presenting as completely as
possible the MUH condition, in both normal-weight and
overweight-obese people. Also, rigorous criteria for deﬁning
MH condition in a general population cohort were adopted,
and many diﬀerent metabolic and cardiovascular values were
considered. In particular, with respect to MH participants,
the MUH-O participants were older and more frequently of
male gender and had higher degrees of central obesity, a
more sedentary lifestyle, insulin resistance, and liver steato-
sis. Despite the low risk proﬁle, we cannot aﬃrm that MH-
O has a benign prognosis and an attitude of caution towards
this condition is merited. In fact, recent studies suggest that
MH-O is a transient state [50, 51], so that it needs to be
treated like MUH-O, as no clear evidence exists that MH
condition has a favorable prognosis in the long run in terms
of evolution towards diabetes [9, 52] and cardiovascular
events [53, 54]. However, more extensive longitudinal studies
are needed to clarify this.
Our study has some important limitations. The cross-
sectional design did not allow us to establish any cause-
eﬀect relationship. Though we investigated a cohort whose
characteristics resembled those of the general population,
the modality of cohort recruitment did not allow us to aﬃrm
that our cohort was fully representative of the general
population.
In conclusion, our study may contribute to improving the
diagnosis of obesity in terms of metabolic health and to iden-
tifying those patients with higher metabolic and cardiovascu-
lar risk who need more in-depth strategies of treatment. In
addition, we found that a signiﬁcant number of normal-
weight people are MUH; therefore, preventive strategies
at the population level should also include an appropriate
identiﬁcation of this high-risk subgroup of people. Longi-
tudinal studies on large cohorts of general populations will
help to deﬁnitively clarify the real clinical importance of
classifying people based on metabolic health.
1.4
A
BI
r = −0.07
P < 0.05
1.3
1.2
1.1
1.0
0.9
0.8
0.7
0.6
0.0 0.5 1.0 1.5 2.52.0
c-IMT (mm)
Figure 1: Correlation between the ankle-brachial index (ABI) and
carotid intima-media thickness (c-IMT) in the cohort.
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